Pharma BD Deal Intelligence
A small regional licensing deal (not the GSK $5.1B TESARO buyout) that eventually delivered a real but unspectacular APAC product launch
Full analysis, sources & comparables →TESARO landed licensing and supply agreements for Zejula in Japan and select APAC markets, with Takeda paying $100M upfront and up to $240M in milestones plus…
Jefferies analysts said the $100M upfront should give TESARO adequate cash to operate through approximately 2018 and that the deal 'indicates unlikely…
Manufacturers of niraparib (Zejula), olaparib (Lynparza) and rucaparib (Rubraca) voluntarily withdrew indications for heavily pretreated BRCA-mutated advanced…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
TESARO licensed Japan rights for niraparib in all tumor types and South Korea/Taiwan/Russia/Australia rights in all tumors except prostate cancer to Takeda. TESARO received $100M upfront plus up to $240M in regulatory and commercial milestones, plus tiered double-digit royalties on Takeda territory net sales. Niraparib is the PARP inhibitor approved as ZEJULA in ovarian cancer maintenance.
A small regional licensing deal (not the GSK $5.1B TESARO buyout) that eventually delivered a real but unspectacular APAC product launch
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd. / Tesaro Inc. (this deal) | 2017 | $340M | 54 |
| Takeda Pharmaceutical Company Ltd. / Nimbus Lakshmi | 2022 | $6.0B | 82 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
| Takeda Pharmaceutical Company Ltd. / Nycomed | 2011 | $13.7B | 72 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
| Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. | 2018 | $1.2B | 64 |
← Browse all deals · How we score deals
More: 2017 deals · Takeda Pharmaceutical Company Ltd. deals · Oncology deals